Cargando…
Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragm...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028417/ https://www.ncbi.nlm.nih.gov/pubmed/29988633 http://dx.doi.org/10.1002/ccr3.1627 |